Abstract
Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the therapy of multiple myeloma and mantle cell lymphoma, there are still no DUB inhibitors endorsed for clinical usage. Since deubiquitinating enzymes (DUBs) are becoming as a new class of modifiers in the UPS, potential drugs that target specific DUBs have been investigated with the development of experimental technologies for screening small inhibitor molecules. However, the molecular mechanisms of these molecules are poorly understood. In order to design and develop specific small inhibitor molecules for specific DUBs, identification of specific substrates and molecular structures for each DUB is required. Here, we review structures, substrates, and small inhibitor molecules of DUBs identified up to date, providing a clear rationale for the development of novel small inhibitor molecules of DUBs for cancer.
Keywords: Deubiquitination, Inhibitor, JAMM, Josephin, OTU, UCH, USP.
Current Pharmaceutical Design
Title:Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Volume: 19 Issue: 22
Author(s): Key-Hwan Lim and Kwang-Hyun Baek
Affiliation:
Keywords: Deubiquitination, Inhibitor, JAMM, Josephin, OTU, UCH, USP.
Abstract: Abnormal regulation of the ubiquitin-proteasome system (UPS) has been known to be involved in the pathogenesis of a variety of human diseases. A number of studies have focused on the identification of small modifiers for the UPS. Even though the proteasome inhibitor Bortezomib (Velcade®) has been approved for the therapy of multiple myeloma and mantle cell lymphoma, there are still no DUB inhibitors endorsed for clinical usage. Since deubiquitinating enzymes (DUBs) are becoming as a new class of modifiers in the UPS, potential drugs that target specific DUBs have been investigated with the development of experimental technologies for screening small inhibitor molecules. However, the molecular mechanisms of these molecules are poorly understood. In order to design and develop specific small inhibitor molecules for specific DUBs, identification of specific substrates and molecular structures for each DUB is required. Here, we review structures, substrates, and small inhibitor molecules of DUBs identified up to date, providing a clear rationale for the development of novel small inhibitor molecules of DUBs for cancer.
Export Options
About this article
Cite this article as:
Lim Key-Hwan and Baek Kwang-Hyun, Deubiquitinating Enzymes as Therapeutic Targets in Cancer, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220013
DOI https://dx.doi.org/10.2174/1381612811319220013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
Current Cancer Therapy Reviews Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets The Mechanism by which the Phenothiazine Thioridazine Contributes to Cure Problematic Drug-Resistant Forms of Pulmonary Tuberculosis: Recent Patents for “New Use”
Recent Patents on Anti-Infective Drug Discovery Tetrapyrrolic Macrocycles: Potentialities in Medical Imaging Technologies
Current Organic Synthesis Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation
Current Pharmaceutical Biotechnology Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Drug Repurposing in Chemical Genomics: Can We Learn from the Past to Improve the Future?
Current Topics in Medicinal Chemistry Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Soft Bipolar Spectrum and Staging in Bipolar Disorder
Current Psychiatry Reviews Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Disseminated Intravascular Coagulation in Leukemia and Sepsis
Vascular Disease Prevention (Discontinued) Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Outlook on Epigenetic Therapeutic Approaches for Treatment of Gastric Cancer
Current Cancer Drug Targets High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: A Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four α-Helices in a Bundle
Protein & Peptide Letters